SHR6508

DRUG2 trials

Sponsors

Shanghai Hengrui Pharmaceutical Co., Ltd.

Conditions

Secondary HyperparathyroidismSecondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis

Phase 2

A Study of SHR6508 in Secondary Hyperparathyroidism

Shanghai Hengrui Pharmaceutical Co., Ltd.Secondary Hyperparathyroidism

Start: 2023-02-24End: 2023-11-30Updated: 2023-06-18

Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical Trial

CompletedNCT06236295

Shanghai Hengrui Pharmaceutical Co., Ltd.Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis

Start: 2024-02-20End: 2025-11-13Updated: 2026-05-20